Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies

Naomi E. Allen*, Ruth C. Travis, Paul N. Appleby, Demetrius Albanes, Matt J. Barnett, Amanda Black, H. Bas Bueno-de-Mesquita, Melanie Deschasaux, Pilar Galan, Gary E. Goodman, Phyllis J. Goodman, Marc J. Gunter, Markku Heliovaara, Kathy J. Helzlsouer, Brian E. Henderson, Serge Hercberg, Paul Knekt, Laurence N. Kolonel, Christina Lasheras, Jakob LinseisenE. Jeffrey Metter, Marian L. Neuhouser, Anja Olsen, Valeria Pala, Elizabeth A. Platz, Harri Rissanen, Mary E. Reid, Jeannette M. Schenk, Meir J. Stampfer, Par Stattin, Catherine M. Tangen, Mathilde Touvier, Antonia Trichopoulou, Piet A. van den Brandt, Timothy J. Key

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade. Methods: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided. Results: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, P-heterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, P-trend
Original languageEnglish
Article numberdjw153
JournalJournal of the National Cancer Institute
Issue number11
Publication statusPublished - Nov 2016


Dive into the research topics of 'Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies'. Together they form a unique fingerprint.

Cite this